Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Sponsor
Hoffmann-La Roche
Study ID
NCT04091217
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
  • Bevacizumab — DRUG
    Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.

Study Details

This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma.

Key Dates

Start date
Nov 25, 2019
Status verified
Aug 2024
Primary completion
Aug 31, 2022
Completion
Sep 1, 2023

Study Design

Enrollment
43 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab + Bevacizumab

Primary Outcome Measure

Objective Response Rate (ORR) in the Full Analysis Set Analysis Population [ Time Frame: Up to approximately 32 months ]

Related Studies